Table 5 Pharmacokinetic results of treosulfan stratified by BSA-dependent dose group (non-compartmental analysis).

From: Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

Mean ± SD, tmax: median (range)

10 g/m²

12 g/m²

14 g/m²

N

5

23a

26

Cmax [µg/mL]

700 ± 218

634 ± 192

650 ± 98

tmax [h]

2.28 (2.00–2.30)

2.00 (2.00–2.50)

2.02 (2.00–2.65)

AUClast [µg h/mL]

1686 ± 345

1599 ± 33

1848 ± 283

AUC∞ [µg h/mL]

1700 ± 351

1627 ± 344

1900 ± 296

t1/2term [h]

1.15 ± 0.12

1.38 ± 0.21

1.59 ± 0.18

CL [L/h]

2.33 ± 0.60

5.3 ± 1.35

10.94 ± 2.41

Vd [L]

3.86 ± 1.11

10.78 ± 3.69

25.24 ± 6.64

  1. aN = 25 for AUC∞, t1/2term, CL, Vd.
  2. SD standard deviation, tma time to reach maximum plasma concentration, N number of subjects, Cmax maximum plasma concentration, h hour, AUC area under the curve, AUClas AUC from time 0 to the time of the last measurable plasma concentration, AUC∞ AUC from time 0 to infinite time, t1/2term apparent terminal elimination half-life, CL total clearance; Vd volume of distribution.
Back to article page